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Abstract
The generation of stereochemically-rich benzothiaoxazepine-1,1′-dioxides for enrichment of high-
throughput screening collections is reported. Utilizing a microwave-assisted, continuous flow
organic synthesis platform (MACOS), scale-out of core benzothiaoxazepine-1,1′-dioxide scaffolds
has been achieved on multi-gram scale using an epoxide opening/SNAr cyclization protocol.
Diversification of these sultam scaffolds was attained via a microwave-assisted intermolecular
SNAr reaction with a variety of amines. Overall, a facile, 2-step protocol generated a collection of
benzothiaoxazepine-1,1′-dioxides possessing stereochemical complexity in rapid fashion, where
all 8 stereoisomers were accessed from commercially available starting materials.
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1. Introduction
The design, synthesis and production of molecular libraries for high-throughput biological
screening (HTS) has been a critical aspect of drug discovery.i A recent survey of current
compound collections for HTS has found that on average, they posses a higher sp2 content
as well as lower structural and stereochemical complexity when compared to currently
available drugs.ii While enrichment of compound collections with natural products and their
derivatives is one way to enhance complexity, the aforementioned dichotomy has warranted
the development of efficient synthetic methods of increasing stereochemical complexity and
sp3 content in screening collections.iii,iv We herein report a facile, 2-step protocol to
generate a collection of benzothiaoxazepine-1,1′-dioxides possessing stereochemical
complexity in rapid fashion. A microwave-assisted, continuous flow organic synthesis
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(MACOS) platform is employed to produce all 8 stereoisomers of a benzothiaoxazepine-1,1-
dioxide core scaffold via an epoxide opening/SNAr cyclizationv protocol, followed by
intermolecular SNAr diversification.
Diversity-oriented synthesis (DOS) has emerged in recent years as a powerful tool to enrich
the diversity of molecules for HTS.vi This approach has been led by the development of new
methodologies, automated technologies, and collaborations within the area of chemical
biology. In addition to structural diversity and complexity, the ability to rapidly access every
potential stereoisomer of a structure, while functionalizing a core scaffold at every position,
is a key concept at the heart of DOS that has the potential to benefit both early stage HTS
and SAR, as well as downstream probe/drug development.iv,vi,vii
It was envisioned that a collection of stereochemically-rich benzofused sultams could be
rapidly generated where every stereoisomer is readily accessible from commercially
available starting materials. In this regard, utilizing a combination of chiral 2° sulfonamides,
epoxides, and amino alcohols, a two-step procedure was designed for the synthesis of core
benzothiaoxazepine-1,1-dioxides via an epoxide opening/ SNAr cyclizationv sequence,
followed by intermolecular SNAr diversification (Figure 1). Furthermore, the powerful
combination of microwave heating and flow chemistry was seen to achieve this goal quickly
through shortened reaction times and production at any scale necessary with no process re-
optimization.
2. Results and Discussion
Preliminary investigations focused on addressing the ability to generate multi-gram
quantities of core benzothiaoxazepine-1,1-dioxide scaffolds. Initial efforts in batch
microwave were limited by reactor size and decreased yields resulting from increased by-
product formation during scale-up.viii To address these limitations, the MACOS platform
was employed to scale-out, rather than scale-up, the scaffold production runs.ix,x The scale-
out approach to microwave transformations has been shown in recent years to be a highly
efficient method for accessing large quantities of organic molecules.xi,xii
At the outset, a batch microwave reactor was used to develop reactions times that would be
suitable for adaptation to flow (Table 1). With some optimization, it was determined that
benzothiaoxazepine-1,1-dioxides 2 could be generated in 70% yield (100% conversion
based on 1) utilizing 1.5 equiv. of tBuOK at 180 °C for 1 minute in the microwave (Table 1,
entry 7). Such conditions are well tolerated in the MACOS reactor system where flow rates
can be set to establish average residence times of approximately one minute for material in
the irradiation zone of the microwave (where the sample is actually being irradiated and thus
heated).
Taking these preliminary conditions into the MACOS platform, a variety of reactor
parameters were investigated, namely flow rate, temperature and power to fine-tune the
scale-out protocol (Table 2). When shorter production runs were performed (eg., to produce
~200 mg of 2), the desired sultam was generated in 50% yield (100% conversion of 1)
utilizing a flow rate of 150 μL/min at 190 °C and 220 Watts of power (Table 2, entry 7).xiii
When the MACOS reaction was performed for longer times to increase product output,
clogging of reaction capillaries was observed after approximately 3 mL of the reaction
solution had been flowed. When isolated, this material was not soluble in an array of
solvents, indicating that product decomposition under these conditions may have occurred.
Suspecting that this problem might be related to the base, tBuOK was substituted with DBU.
Re-optimization of reaction conditions in batch utilizing DBU (Table 1, entries 8–11) was
carried out and the best conditions for the generation of 3 were attempted using the MACOS
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platform leading to a gratifying 78% yield (Table 2, Entry 8). Utilizing 1.5 equiv of DBU at
180 °C with a flow rate of 100–200μL/min, benzothiaoxazepine-1,1′-dioxides 2–5 were
synthesised in gram quantities demonstrating the successful application of the MACOS
platform for scale-out (Scheme 1). Building on these trial runs, benzothiaoxazepine-1,1-
dioxides core scaffolds 6 – 13 , were prepared readily using optically-pure epoxides on the
MACOS platform (Scheme 1).xiv
With these benzothiaoxazepine-1,1′-dioxide core scaffolds in hand, diversification via
microwave-assisted SNAr was investigated.xv Utilizing the Anton Parr Synthos 3000®
microwave platform, a collection of eight optically pure, stereoisomeric sultams (14 – 21)
was produced demonstrating facile access to stereochemically-rich small-molecule
collections for HTS (Scheme 2). Reactions were carried out on 100 mg scale in DMSO at
180 °C for 50 minutes, followed by dilution, filtration, and purification by column
chromatography to produce the desired benzothiaoxazepine-1,1-dioxides 14 – 21 in high
yield.
3. Conclusions
In conclusion, a method for the rapid access of stereochemically-rich
benzothiaoxazepine-1,1′-dioxides utilizing a two-step, microwave-accelerated protocol is
reported. A MACOS platform was used for the scale-out production of core
benzothiaoxazepine-1,1′-dioxide scaffolds on multi-gram scale using a cascade epoxide
opening/cyclization sequence. These core scaffolds were subsequently diversified by a
microwave-assisted, intermolecular SNAr reaction with chiral, non-racemic amino alcohols.
Overall, this 2-step protocol efficiently generated all 8 stereoisomers of
benzothiaoxazepine-1,1′-dioxides in optically-pure form, bearing three stereogenic centers,
using readily accessible starting materials. These compounds will be evaluated by HTS for
potential biological activity by our collaborators, and these results will be reported in due
course.
4. Experimental
Microwave irradiation experiments and Analysis of Compounds 2 – 13
All MACOS experiments were performed in 1700 μ m (ID) borosilicate capillaries, using a
single mode Biotage Smith Creator Synthesizer, operating at a frequency of 2.45 GHz with
irradiation power from 0 to 350 W. The capillary was fed reactants from Hamilton gastight
syringes attached to a Harvard 22 syringe pump preset to the desired flow rate. The system
was connected to a sealed collection vial, where a pressurized air line (75 psi) was attached
to create backpressure. The temperatures reported were measured off the surface of the
capillaries by the IR sensor built into the microwave chamber. All reagents and solvents
were purchased from commercial sources and used without additional purification. Column
chromatography purifications were carried out using the flash technique on silica gel 60
(200–400 mesh). 1H and 13C NMR spectroscopy was performed on a Bruker Avance 400
MHz instrument (at 400 MHz and 100 MHz respectively) or a Bruker DRX-500
spectrometer (at 500 MHz or 125 MHz respectively). All 1H NMR spectra were calibrated
to the signal from the residual proton of the deuterated chloroform solvent (7.26 ppm)
while 13C NMR spectra were calibrated to the middle carbon signal of the triplet for
deuterated chloroform (77.00 ppm). High-resolution mass spectrometry (HRMS) was
recorded on a LCT Premier Spectrometer (Micromass UK Limited) operating the the ESI
mode (MeOH). All compounds in this study have been isolated by silica gel/aluminum
oxide chromatography for the purpose of spectroscopic identification
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General Methods for compounds 14 - 21
All reactions were carried out in 1 dram vials using a reaction heating block in an Anton
Paar ® Synthos 3000 synthesizer. Parallel evaporations were performed using a GeneVac
EZ-2 Plus evaporator. All reagents and solvents were purchased from commercial sources
and used without additional purification. Flash column chromatography was performed on
silica gel (30930M-25, Silica Gel 60A, 40-63 um) and thin layer chromatography was
performed on silica gel 60F254 plates (EM-5717, Merck). Deuterated solvents were
purchased from Cambridge Isotope laboratories. 1H and 13C NMR spectra were recorded in
CDCl3 (unless otherwise mentioned) on a Bruker DRX-500 spectrometer operating at 500
MHz, and 125 MHz, respectively, and calibrated to the solvent peak. High-resolution mass
spectrometry (HRMS) was recorded on a LCT Premier Spectrometer (Micromass UK
Limited) operating in the ESI mode (MeOH). Optical rotations at 589 nm, were measured
using AUTOPOL IV Model automatic polarimeter. IR spectra were recorded on a Shimadzu
FTIR-8400S instrument.
General procedure A: Scale-out synthesis of benzothiaoxazepine-1,1-dioxide derivatives 2
–13 utilizing MACOS flow-platform
A stock solution containing the sulfonamide (1.0 equiv.), epoxide (3 equiv.) and DBU (1.5
equiv.) in DMSO, (0.3-0.4 M) was prepared and loaded into a 10 mL Hamilton gastight
syringe. The tubing was primed with DMSO and the syringe was connected to the reactor
system with the aid of Microtight™ fittings. A sealed collection vial was connected to the
system, where a pressurized airline (75 psi) was attached to create backpressure. A Harvard
22 syringe pump was set to deliver the reaction solution at a rate of 100-200 μ L/min (see
Table 1 and 2 for specific conditions). The single mode microwave was programmed to heat
constantly with the power level controlled manually so as to keep the temperature constant
at the specified levels (see Scheme 1 and Table 2 for specific conditions). The effluent from
the reactor was fed into a sealed vial and analyzed directly by 1H NMR spectroscopy
immediately after the reaction. The crude reaction mixture was collected and the product
was purified by neutral aluminum oxide column chromatography.
7-Bromo-2-butyl-4-ethyl-1,2- benzoxathiazepine-1,1-dioxide (2)
Utilizing General Procedure A, sultam 2 was isolated in 60% yield (2.8 g, 7.76 mmol) as a
yellow solid. FTIR (neat): 2960, 2933, 1573, 1460, 1342, 1164, 1058 cm-1; 1H NMR (300
MHz CDCl3) δ 7.70 (d, J = 8.1 Hz, 1H), 7.37-7.28 (m, 2H), 4.01-3.82 (m, 2H), 3.29-3.17
(m, 2H), 2.85-2.74 (m, 1H), 1.83-1.71 (m, 1H), 1.67-1.53(m, 3H), 1.42-1.27 (m, 2H), 1.17
(t, J =7.2 Hz, 3H), 0.95 (t, J = 7.2 Hz, 3H) ppm; 13C NMR (75 MHz CDCl3) δ 156.1,
133.5, 130.0, 127.4, 127.2, 123.8 80.9, 53.2, 48.2, 30.8, 26.4, 19.6, 13.7, 10.2 ppm;
DEPT 13C NMR (75 MHz CDCl3) δ 130.1, 127.3, 126.5, 80.9, 53.2, 48.2, 30.8, 26.4, 19.6,
13.7, 10.2 ppm; HRMS calculated for C14H21BrNO3S (M+H)+ 362.0426; found 362.0429
(TOF MS ES+).
4-(Butoxymethyl)-7-bromo-2-butyl-1,2-benozoxathiazephine-1,1-dioxide (3)
Utilizing General Procedure A, sultam 3 was isolated in 64% yield (3.45 g, 8.234 mmol) as
a colorless viscous oil. FTIR (neat): 2956, 2871, 1577, 1456, 1344, 1164, 1058, 931
cm-1; 1H NMR (300 MHz CDCl3) δ 7.69 (d, J = 9.0 Hz, 1H), 7.37 (m, 2H), 4.22-4.15 (m,
1H), 3.96 (dd, J = 15, 10.5 Hz, 1H), 3.74-3.69 (m, 1H), 3.59-3.46 (m, 3H), 3.43 (d, J = 15
Hz, 1H), 3.26-3.16 (m, 1H), 2.82-2.61 (m, 1H), 1.61-152 (m, 4H), 1.51-1.72 (m, 4H),
0.98-0.83 (m, 6H) ppm; 13C NMR (75 MHz CDCl3) δ 155.5, 133.34, 130.1, 127.4, 126.6,
77.8, 71.7, 70.6, 50.5, 48.0, 31.6, 30.7, 19.6, 19.3, 13.8, 13.6 ppm; DEPT 13C NMR (75
MHz CDCl3) δ 130.1, 127.5, 126.7, 77.8, 71.7, 70.6, 50.5, 48.0, 31.6, 30.7, 19.6, 19.3, 13.9,
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13.6 ppm; HRMS calculated for C17H27BrNO4S (M+H)+ 420.0844; found 420.0842 (TOF
MS ES+).
2-Butyl-4-ethyl-7-fluoro-1,2- benzoxathiazepine-1,1-dioxide (4)
Utilizing General Procedure A, sultam 4 was isolated in 54% yield (2.6 g, 8.64 mmol) as a
colorless viscous oil. FTIR (neat): 2962, 2873, 1598, 1583, 1342, 1141, 1070, 995 cm-1; 1H
NMR (300 MHz CDCl3) δ 7.83 (dd, J = 8.7, 6.3 Hz, 1H), 6.94-6.83 (m, 2H), 3.98-3.81 (m,
2H), 3.28-3.18 (m, 2H), 2.81-2.74 (m, 1H), 1.79-1.72 (m, 1H) 1.64-1.54 (m, 3H), 1.38-1.31
(m, 2H), 1.5 (t, J =7.2 Hz, 3H), 0.94 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz CDCl3) δ 167.
(d, JC-F = 253.5 Hz), 157.4 (d, JC-F = 12.0 Hz), 130.9 (d, JC-F = 10.5 Hz), 130.6 (d, JC-F
=3.7 Hz), 111.4 (d, JC-F = 21.5 Hz), 110.8 (d, JC-F = 23.2 Hz), 80.9, 53.1, 48.1, 30.7, 26.3,
19.6, 13.6, 10.1 ppm; DEPT 13C-NMR (75 MHz CDCl3) δ 130.9 (d, JC-F = 10.5 Hz),
111.4 (d, JC-F = 21.8 Hz), 110.8 (d, JC-F = 22.5 Hz), 80.9, 53.1, 48.2, 30.8, 26.3, 19.6, 13.6,
10.2 ppm; CHN analysis calculated for C14H20FNO3S: C, 55.79; H, 6.69; N, 4.65; S, 10.65:
found C, 56.01; H, 6.42; N, 4.53; S, 10.72.
4-(Butoxymethyl)-2-butyl-7-fluoro-1,2-benozoxathiazephine-1,1-dioxide (5)
Utilizing General Procedure A, sultam 5 was isolated in 52% yield (3.0 g, 8.36 mmol) as a
colorless viscous oil; FTIR (neat): 2958, 2933, 2871, 1598, 1585, 1423, 1344, 1118, 1070,
989 cm-1; 1H NMR (300 MHz CDCl3) δ 7.82 (dd, J = 8.7, 6.3 Hz, 1H), 6.93 - 6.84 (m, 2H),
4.21 (m, 1H), 3.95 (d, J = 15, 10.5 Hz, 1H), 3.73 - 3.67 (m, 1H), 3.57 - 3.48 (m, 3H), 3.62 -
3.42 (dd, J = 15, 1.3 Hz, 1H), 3.17 (m, 1H), 2.77 – 2.72 (m, 1H), 1.59 – 1.52 (m, 4H),
1.41-1.32 (m, 4H), 0.94 - 0.87 (m, 6H), ppm; 13C NMR (75 MHz CDCl3) δ 167.1 (d, JC-F
= 253.5 Hz), 156.9 (d, JC-F = 12.0 Hz), 130.9 (d, JC-F = 10.5 Hz), 130.5 (d, JC-F = 3.0 Hz),
111.6 (d, JC-F = 21.8 Hz), 111.1 (d, JC-F = 23.3 Hz), 77.7, 71.6, 70.6, 50.4, 47.9, 31.6, 30.6,
19.6, 19.2, 13.8, 13.6 ppm; DEPT 13C NMR (75 MHz CDCl3) δ 130.9 (d, JC-F = 10.5 Hz),
111.6 (d, JC-F = 22.5 Hz), 111.1 (d, JC-F = 22.5 Hz), 77.7, 71.6, 70.6, 50.4, 47.9, 31.6, 30.7,
19.6, 19.2, 13.9, 13.6 ppm; CHN analysis calculated for C17H26FNO4S: C, 56.80; H, 7.29;
N, 3.90; S, 8.92: found C, 57.18; H, 7.43; N, 3.96; S, 8.85.
((R)-4-(Benzyloxymethyl)-7-fluoro-2-((R)-1-pentylethyl)-1,2-benzoxathiazepine-1,1-dioxide
(6)
Utilizing general procedure A, sultam 6 was isolated in 50% yield (3.01 g, 6.92 mmol) as a
colorless viscous oil; [α]D20 = + 6.4° (c = 2.7, CHCl3); FTIR (neat): 2929, 2860, 1598,
1471, 1340, 1157, 1116, 1072 cm-1; 1H NMR (400 MHz CDCl3) δ 7.84 (dd, J = 6.4, 8.4
Hz, 1H), 7.42 - 7.35 (m, 5H), 6.92 - 6.85 (m, 2H), 4.65 (s, 2H), 4.33 - 4.31 (m, 1H), 4.29 -
4.14 (m, 1H), 3.84 - 3.77 (m, 2H), 3.67-3.66 (m, 1H), 3.47 (dd, J =14.0, 1.7 Hz, 1H), 1.60
(br s, 1H), 1.50 (m, 1H), 1.29 (br s, 6H), 1.0 (d, J = 6.8 Hz, 3H), 0.89 (t, J = 6.8 Hz,
3H); 13C NMR (100 MHz CDCl3) δ 166.2 (d, JC-F = 253.0 Hz), 156.6 (d, JC-F = 12 Hz),
137.4, 133.3 (d, JC-F = 3 Hz), 128.8 (d, J = 11 Hz), 128.4, 127.9, 127.6, 111.1 (d, JC-F = 22
Hz), 110.4 (d, JC-F = 23 Hz), 80.7, 73.6, 70.1, 54.4, 44.8, 34.5, 31.2, 25.7, 22.4, 19.8, 13.9




Utilizing General Procedure A, sultam 7 was isolated in 51% yield (3.05 g, 7.01 mmol) as a
colorless viscous oil; [α]D20 = - 10.3° (c = 4.7, CHCl3); FTIR (neat): 2929, 2861, 1561,
1470, 1340, 1156, 1116, 1073 cm-1; 1H NMR (300 MHz CDCl3) δ 7.83 (dd, J = 8.7, 6.3
Hz, 1H), 7.41 - 7.34 (m, 5H), 6.89-6.79 (m, 2H), 4.77 - 4.73 (m, 1H), 4.66 (d, J = 3.6, Hz,
2H), 4.10 (m, 1H), 3.78 - 3.59 (m, 3H), 3.45 (dd, J =14.1, 3.0 Hz, 1H), 1.43 - 1.26 (m, 8H),
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1.10 (d, J = 6.6 Hz, 3H), 0.89 (t, J = 6.6 Hz, 3H) ppm; 13C NMR (100 MHz CDCl3) δ
166.0(d, JC-F = 252.0 Hz), 156.5 (d, JC-F = 13 Hz), 137.5, 131.7, 129.1 (d, JC-F = 11 Hz,
1H), 128.4, 127.9, 127.5, 110.6 (d, JC-F = 22 Hz), 109.3 (d, JC-F = 24 Hz), 80.6, 73.5, 69.9,
54.9, 44.6, 35.3, 31.2, 26.1, 22.4, 18.6, 13.9 ppm; CHN analysis calculated for




Utilizing General Procedure A, sultam 8 was isolated in 53% yield (3.15 g, 7.24 mmol) as a
colorless viscous oil; [α]D20 = + 7.6° (c = 2.2, CHCl3); FTIR (neat): 2929, 2858, 1600,
1473, 1336, 1157, 1116, 1076 cm-1; 1H NMR (300 MHz CDCl3) δ 7.83 (dd, J = 8.7, 6.3
Hz, 1H), 7.40 - 7.34 (m, 5H), 6.89 - 6.79 (m, 2H), 4.77 - 4.70 (m, 1H), 4.66 (d, J = 3.6 Hz,
2H), 4.10 (m, 1H), 3.78 - 3.59 (m, 3H), 3.45 (dd, J =13.8, 2.8 Hz, 1H), 1.43 - 1.26 (m, 8H),
1.10 (d, J = 6.6 Hz, 3H), 0.89 (t, J = 6.6 Hz, 3H) ppm; 13C NMR (75 MHz CDCl3) δ
166.5(d, JC-F = 252.0 Hz), 156.5 (d, JC-F = 12.8 Hz), 137.5, 131.8 (d, JC-F = 3 Hz), 129.2
(d, JC-F = 10.5 Hz), 128.5, 128.3, 127.9, 127.6, 110.8 (d, JC-F = 22.5 Hz), 109.4 (d, JC-F =
24 Hz), 80.7, 73.6, 69.9, 54.9, 44.6, 35.3, 31.3, 26.1, 22.5, 18.6, 14.0 ppm; DEPT 13C-
NMR (75 MHz CDCl3) δ 129.3 (d, JC-F = 10.5 Hz), 128.6, 128.0, 127.7, 110.8, (d, JC-F =
21.8 Hz), 109.4 (d, JC-F = 23.33 Hz), 80.7, 73.6, 70.0, 55.0, 44.7, 35.4, 31.3, 26.2, 22.5,
18.7, 14.0 ppm; CHN analysis calculated for C23H30FNO4S: C, 63.42; H, 6.94; N, 3.22; S,
7.36: found C, 63.84; H, 6.92; N, 3.14; S, 7.14.
((S)-4-(Benzyloxymethyl)-7-fluoro-2-((S)-1-pentylethyl)-1,2-benzoxathiazepine-1,1-dioxide
(9)
Utilizing General Procedure A, sultam 9 was isolated in 53% yield (3.15 g, 7.24 mmol) as a
colorless viscous oil; [α]D20 = + 26.2° (c = 12.3, CHCl3); FTIR (neat): 2929, 2858, 1596,
1475, 1341, 1157, 1115, 1072 cm-1; 1H NMR (400 MHz CDCl3) δ 7.84 (dd, J = 6.4, 8.4
Hz, 1H), 7.42 - 7.34 (m, 5H), 6.92 - 6.85 (m, 2H), 4.65 (s, 2H), 4.33 - 4.31 (m, 1H), 4.17 -
4.15 (m, 1H), 3.85 - 3.77 (m, 2H), 3.68 (dd, J =10.4, 5.6 Hz, 1H), 3.47 (dd, J = 13.6, 1.7 Hz,
1H), 1.50 - 1.28 (m, 8H), 1.01 (d, J = 6.8 Hz, 3H), 0.89 (t, J = 6.8 Hz, 3H) ppm; 13C NMR
(100 MHz CDCl3) δ 166.2(d, JC-F = 253.0 Hz), 156.6 (d, JC-F = 12.0 Hz), 137.5, 133.3 (d,
JC-F = 2.0 Hz), 128.8 (d, JC-F = 11.0 Hz), 128.4, 127.9, 127.6, 111.1 (d, JC-F = 22.0 Hz),
110.4 (d, JC-F = 23.0 Hz), 80.7, 73.6, 70.1, 54.4, 44.8, 34.5, 31.2, 25.7, 22.4, 19.8, 1.9 ppm;
DEPT 13C-NMR (75 MHz CDCl3) δ 128.8 (d, JC-F = 10.5 Hz), 128.6, 127.9, 127.8, 111.1
(d, JC-F = 21.8 Hz), 110.4 (d, JC-F = 24.0 Hz), 80.8, 73.7, 70.2, 54.4, 44.9, 34.6, 31.2, 25.8,
22.5, 19.9, 13.9 ppm; CHN analysis calculated for C23H30FNO4S: C, 63.42; H, 6.94; N,
3.22; S, 7.36: found C, 63.86; H, 6.81; N, 3.19; S, 7.26.
((R)-4-(Benzyloxymethyl)-2-((S)-1-phenylethyl)-7-fluoro-1,2-benzoxathiazepine-1,1-dioxide
(10)
Utilizing General Procedure A, sultam 10 was isolated in 48% yield (2.85 g, 6.463 mmol) as
a colorless viscous oil; [α]D20 = + 5.8° (c = 3.7, CHCl3); FTIR (neat): 3029, 2937, 2866,
1598, 1585, 1471, 1338, 1174, 1153, 1070 cm-1; 1H NMR (300 MHz CDCl3) δ 7.93 (dd, J
= 8.7, 6.3 Hz, 1H), 7.43 - 7.31 (m, 10H), 6.98 - 6.87 (m, 2H), 5.30 - 5.46 (m, 1H), 4.57 (s,
2H), 4.38 - 4.44 (m, 1H), 3.78 - 3.70 (m, 2H), 3.69 - 3.51 (m, 1H), 3.37 (dd, J = 15.0, 1.8
Hz, 1H), 1.46 (d, J = 6.3 Hz, 3H) ppm; 13C NMR (75 MHz CDCl3) δ 166.9 (d, JC-F =
252.8 Hz), 156.8 (d, JC-F = 12.0 Hz), 139.4, 137.6, 133.3 (d, JC-F = 3.0 Hz),129.1 (d, JC-F =
10.5 Hz), 128.6, 128.5, 128.4, 127.9, 127.8, 127.7, 127.6, 127.5, 111.4 (d, JC-F = 21.8 Hz),
110.9 (d, JC-F = 23.3 Hz), 81.1, 73.5, 70.1, 56.6, 46.1, 17.7 ppm; DEPT 13C-NMR (75
MHz CDCl3) δ 129.1 (d, JC-F = 10.5 Hz), 128.6, 128.5, 128.0, 127.9, 127.6, 127.5, 111.5 (d,
JC-F = 21.8 Hz), 111.0 (d, JC-F = 24.0 Hz), 81.1, 73.5, 70.2, 56.6, 46.1, 17.7 ppm; CHN
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analysis calculated for C24H24FNO4S: C, 65.29; H, 5.48; N, 3.17; S, 7.27: found C, 65.60;
H, 5.38; N, 3.05; S, 7.21.
(S)-4-(Benzyloxymethyl)-2-((R)-1-phenylethyl)-7-fluoro-1,2-benzoxathiazepine-1,1-dioxide
(11)
Utilizing General Procedure A, sultam 11 was isolated in 52% yield (3.10 g, 7.03 mmol) as
a colorless viscous oil; [α]D20 = + 39.2° (c = 6, CHCl3); FTIR (neat): 3020, 2939, 2866,
1596, 1584, 1474, 1338, 1171, 1153, 1070 cm-1; 1H NMR (300 MHz CDCl3) δ 7.94 (dd, J
= 8.7, 6.3 Hz, 1H), 7.41 - 7.15 (m, 10H), 6.99 - 6.93 (m,1H), 6.79 (dd, J = 9.6, 2.4 Hz, 1H),
5.41 (d, J = 2.1 Hz, 1H), 4.50 (d, J = 2.1 Hz, 2H), 3.72 (m, 2H), 3.57 - 3.47 (m, 2H), 3.39 (d,
J = 12.6, Hz, 1H), 1.60 (d, J = 6.9 Hz, 3H) ppm; 13C NMR (75 MHz CDCl3) δ 166.8(d,
JC-F = 253.5 Hz), 156.7 (d, JC-F = 12.0 Hz), 139.0, 137.6, 132.7 (d, JC-F = 3.0 Hz), 129.3 (d,
JC-F = 10.5 Hz), 128.6, 128.4, 128.2, 127.8, 127.6, 127.4, 111.2 (d, JC-F = 22.5 Hz), 110.4
(d, JC-F = 23.3 Hz), 79.4, 73.2, 69.9, 56.6, 45.7, 17.5 ppm; DEPT 13C NMR (75 MHz
CDCl3) δ 129.3 (d, JC-F = 10.5 Hz), 128.6, 128.4, 128.2, 127.8, 127.6, 127.4, 111.2 (d, JC-F
= 21.8 Hz), 110.5 (d, JC-F = 24.0 Hz), 79.5, 73.3, 69.9, 56.6, 45.7, 17.5 ppm; HRMS
calculated for C24H25FNO4S (M+H)+ 442.1488; found 442.1490 (TOF MS ES+).
((R)-4-(Benzyloxymethyl)-2-((S)-1-phenylethyl)-7-fluoro-1,2-benzoxathiazepine-1,1-dioxide
(12)
Utilizing General Procedure A, sultam 12 was isolated in 48% yield (2.84 g, 6.44 mmol) as
a colorless viscous oil; [α]D20 = - 35.0° (c = 4.4, CHCl3); FTIR (neat): 3029, 2935, 2866,
1598, 1585, 1473, 1336, 1155, 1116, 1070 cm-1; 1H NMR (300 MHz CDCl3) δ 7.96 (dd, J
= 8.7, 6.3 Hz, 1H), 7.41 - 7.15 (m, 10H), 6.99 - 6.93 (m, 1H), 6.78 (dd, J = 9.3, 2.7 Hz, 1H),
5.42 - 5.38 (m, 1H), 4.57 (d, J = 2.1 Hz, 2H) 3.67 (s, 2H), 3.55 - 3.45 (m, 2H), 3.38 (d, J =
12.6 Hz, 1H), 1.59 (d, J = 6.9 Hz, 3H) ppm; 13C NMR (75 MHz CDCl3) δ 166.8(d, JC-F =
252.7Hz), 156.7 (d, JC-F = 12.0 Hz), 139.0, 137.6, 132.6 (d, JC-F = 3.0 Hz), 129.3 (d, JC-F =
10.5 Hz), 128.6, 128.5, 128.2, 127.9, 127.6, 127.5, 111.2 (d, JC-F = 22.5 Hz), 110.4 (d, JC-F
= 23.3 Hz), 79.4, 73.2, 69.8, 56.6, 45.7, 17.5 ppm; CHN analysis calculated for




Utilizing general procedure A, sultam 13 was isolated in 54% yield (3.20 g, 7.26 mmol) as a
colorless viscous oil; [α]D20 = - 43.4° (c = 11.3, CHCl3); FTIR (neat): 3028, 2934, 2865,
1597, 1585, 1471, 1339, 1171, 1152, 1070 cm-1; 1H NMR (300 MHz CDCl3) δ 7.92 (m,
1H), 7.42 - 7.30 (m, 10H), 6.98 - 6.85 (m, 2H), 5.52 - 5.45 (m, 1H), 4.57 (s, 2H), 4.38 - 4.33
(m, 1H), 3.77 (m, 2H), 3.56 - 3.51 (m, 1H), 3.40 (dd, J =16.8, 1.8 Hz, 1H), 1.45 (d, J = 6.9
Hz, 3H) ppm; 13C NMR (75 MHz CDCl3) δ 166.9(d, JC-F = 253.5 Hz), 156.7 (d, JC-F = 12
Hz), 139.4, 137.6, 133.2 (d, JC-F = 3 Hz), 129.1 (d, JC-F = 10.5 Hz), 128.6, 128.5, 128.0,
127.9 , 127.6, 127.5, 111.4 (d, JC-F = 22.5 Hz), 110.9 (d, JC-F = 23.3 Hz), 81.1, 73.5, 70.1,
56.6, 46.1, 17.7 ppm; CHN analysis calculated for C24H24FNO4S: C, 65.29; H, 5.48; N,
3.17; S, 7.27: found C, 65.63; H, 5.83; N, 3.15; S, 7.26.
General procedure B: Microwave-assisted diversification of benzothiaoxazepine-1,1-
dioxides 2 -13 cores
Into a 1 dram vial was added benzothiaoxazepine-1,1-dioxide 2 - 13 (100 mg, 0.23 mmol, 1
equiv.), dry DMSO (0.23 ml, 1M), DBU (3.4 μL, 10 mol%) and the corresponding amine (5
equiv., 1.15 mmol). The reaction vessel was capped, placed in Anton Paar Synthos 3000 ®
microwave and heated at 180 °C for 50 min [Power = 1200 W, 8 minute ramp then 50 min
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hold]. After such time, the reaction was diluted in EtOAc, filtered through a SiO2 SPE and
concentrated. The resulting crude product was purified by flash chromatography (7:3,
EtOAc:hexane) to afford the desired benzo-oxathiazepine 1,1-dioxide 14 – 21.
(R)-4-((Benzyloxy)methyl)-7-((S)-2-(hydroxymethyl)pyrrolidin-1-yl)-2-((R)-1-phenylethyl)-3,4-
dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (14)
Utilizing general procedure B, sultam 14 was isolated (92%, 110 mg, 0.21 mmol) as a
colorless viscous oil; [α]D20 = - 21.4° (c = 2.3, CHCl3); FTIR (neat): 3352, 2941, 1596,
1494, 1377, 1326, 1132, 1074 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.66 (d, J = 8.8 Hz,
1H), 7.41 (d, J = 7.3 Hz, 2H), 7.39 – 7.33 (m, 4H), 7.32 (dd, J = 8.0, 2.4 Hz, 2H), 7.32 –
7.27 (m, 2H), 6.44 (dd, J = 8.8, 2.4 Hz, 1H), 6.36 (d, J = 2.3 Hz, 1H), 5.44 (q, J = 7.1 Hz,
1H), 4.56 (q, J = 11.9 Hz, 2H), 4.23 – 4.14 (m, 1H), 3.88 (dd, J = 10.9, 7.1 Hz, 1H), 3.74
(dd, J = 10.2, 5.8 Hz, 1H), 3.72 – 3.62 (m, 2H), 3.54 (dd, J = 12.5, 5.0 Hz, 1H), 3.49 (dt, J =
9.6, 4.8 Hz, 1H), 3.44 (dd, J = 12.1, 5.2 Hz, 1H), 3.21 (ddd, J = 17.2, 11.7, 5.5 Hz, 2H), 2.14
– 2.08 (m, 2H), 2.08 – 2.00 (m, 2H), 1.98 (d, J = 8.4 Hz, 1H), 1.37 (d, J = 7.1 Hz, 3H)
ppm; 13C NMR (126 MHz, CDCl3) δ 156.4, 151.9, 140.2, 137.8, 128.5, 128.4, 127.8,
127.6, 127.5, 127.4, 123.5, 107.1, 105.4, 80.9, 73.4, 70.6, 62.6, 60.3, 56.1, 48.9, 46.3, 28.4,




Utilizing general procedure B, sultam 15 was isolated (95%, 114 mg, 0.218 mmol) as a
colorless viscous oil; [α]D20 = - 3.0° (c = 0.67, CHCl3); FTIR (neat): 3352, 2939, 1598,
1496, 1377, 1326, 1130, 1074 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.68 (d, J = 8.8 Hz,
1H), 7.36 – 7.31 (m, 2H), 7.31 – 7.27 (m, 1H), 7.25 (m, 2H), 7.20 (ddd, J = 10.2, 6.9, 3.7
Hz, 5H), 6.41 (dt, J = 10.3, 5.1 Hz, 1H), 6.22 (d, J = 2.4 Hz, 1H), 5.34 (q, J = 7.0 Hz, 1H),
4.45 (q, J = 12.1 Hz, 2H), 3.90 – 3.84 (m, 1H), 3.90 – 3.83 (m, 1H), 3.64 (dd, J = 27.2, 12.0
Hz, 2H), 3.53 (ddd, J = 14.0, 13.2, 7.8 Hz, 2H), 3.45 (dq, J = 10.5, 5.3 Hz, 2H), 3.27 (d, J =
12.5 Hz, 1H), 3.22 – 3.14 (m, 1H), 2.08 (dt, J = 8.4, 4.3 Hz, 2H), 2.06 – 1.98 (m, 2H), 1.64
(d, J = 4.2 Hz, 1H), 1.55 (d, J = 7.0 Hz, 3H) ppm; 13C NMR (126 MHz, CDCl3) δ 156.3,
151.6, 139.8, 137.8, 128.6, 128.4, 127.8, 127.7, 127.7, 127.4, 122.7, 107.0, 104.7, 79.0,
73.1, 70.2, 62.7, 59.9, 56.3, 48.9, 45.9, 28.4, 23.3, 17.7 ppm; HRMS calculated for
C29H35N2O5S (M+H)+ 523.2267; found 523.2258 (TOF MS ES+).
(S)-4-((Benzyloxy)methyl)-7-((S)-2-(hydroxymethyl)pyrrolidin-1-yl)-2-((S)-1-phenylethyl)-3,4-
dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (16)
Utilizing general procedure B, sultam 16 was isolated (90%, 108 mg, 0.207 mmol) as a
colorless viscous oil; [α]D20 = - 27.0° (c = 0.51, CHCl3); FTIR (neat): 3353, 2939, 1596,
1496, 1377, 1326, 1130, 1074 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.66 (dd, J = 8.7, 4.5
Hz, 1H), 7.38 (d, J = 7.1 Hz, 2H), 7.36 – 7.31 (m, 4H), 7.31 – 7.25 (m, 4H), 6.40 (dd, J =
8.8, 2.4 Hz, 1H), 6.35 (d, J = 2.4 Hz, 1H), 5.42 (q, J = 7.1 Hz, 1H), 4.57 – 4.50 (m, 2H),
4.17 (ddd, J = 9.4, 4.7, 3.3 Hz, 1H), 3.89 (dt, J = 11.3, 5.6 Hz, 1H), 3.73 – 3.60 (m, 3H),
3.60 – 3.54 (m, 1H), 3.47 (dd, J = 10.1, 6.2 Hz, 2H), 3.22 – 3.16 (m, 2H), 2.09 (tt, J = 10.4,
5.0 Hz, 2H), 2.08 – 2.04 (m, 2H), 1.55 (t, J = 5.2 Hz, 1H), 1.36 (d, J = 7.1 Hz, 3H) ; 13C
NMR (126 MHz, CDCl3) δ 156.4, 151.8, 140.1, 137.8, 128.5, 128.4, 127.8, 127.7, 127.6,
127.5, 123.7, 107.1, 105.5, 80.9, 73.4, 70.5, 62.8, 60.0, 56.1, 49.0, 46.3, 28.4, 23.3, 17.4
ppm; HRMS calculated for C29H35N2O5S (M+H)+ 523.2267; found 523.2260 (TOF MS ES
+).
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Utilizing general procedure B, sultam 17 was isolated (98%, 117 mg, 2.25 mmol) as a
colorless viscous oil; [α]D20 = - 36.5° (c = 0.79, CHCl3); FTIR (neat): 3363, 2933, 1598,
1494, 1377, 1325, 1132, 1076 cm-1; 1H NMR (500 MHz CDCl3) δ 7.67 (t, J = 6.6 Hz, 1H),
7.36 – 7.32 (m, 2H), 7.31 – 7.27 (m, 1H), 7.24 (m, 2H), 7.23 – 7.20 (m, 3H), 7.20 – 7.16 (m,
2H), 6.42 (dt, J = 15.3, 7.7 Hz, 1H), 6.21 (d, J = 2.4 Hz, 1H), 5.32 (q, J = 7.0 Hz, 1H), 4.44
(q, J = 12.1 Hz, 2H), 3.90 – 3.83 (m, 1H), 3.68 – 3.57 (m, 3H), 3.53 (dq, J = 10.5, 5.1 Hz,
2H), 3.46 – 3.41 (m, 2H), 3.26 (d, J = 12.5 Hz, 1H), 3.20 – 3.13 (m, 1H), 2.12 – 1.96 (m,
4H), 1.64 (s, 1H), 1.55 (d, J = 7.0 Hz, 3H) ppm; 13C NMR (126 MHz, CDCl3) δ 156.3,
151.6, 139.8, 137.9, 128.6, 128.5, 128.4, 127.8, 127.7, 127.4, 122.8, 107.0, 104.6, 78.9,
73.0, 70.3, 62.7, 60.1, 56.3, 48.9, 45.9, 28.4, 23.3, 17.6.ppm; HRMS calculated for
C29H35N2O5S (M+H)+ 523.2267; found 523.2261 (TOF MS ES+).
(R)-4-((Benzyloxy)methyl)-7-((R)-2-(hydroxymethyl)pyrrolidin-1-yl)-2-((R)-1-phenylethyl)-3,4-
dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (18)
Utilizing general procedure B, sultam 18 was isolated (93%, 111 mg, 0.214 mmol) as a
colorless viscous oil; [α]D20 = + 28.5° (c = 2.4, CHCl3); FTIR (neat): 3348, 2937, 2871,
1596, 1496, 1377, 1326, 1130, 1074 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.63 (d, J = 8.8
Hz, 1H), 7.38 (d, J = 7.3 Hz, 2H), 7.34 (ddd, J = 7.4, 4.5, 2.0 Hz, 4H), 7.31 – 7.28 (m, 2H),
7.28 – 7.25 (m, 2H), 6.39 (dt, J = 10.3, 5.2 Hz, 1H), 6.35 (d, J = 2.3 Hz, 1H), 5.42 (q, J = 7.1
Hz, 1H), 4.58 – 4.49 (m, 2H), 4.19 – 4.13 (m, 1H), 3.91 – 3.83 (m, 1H), 3.55 – 3.49 (m, 3H),
3.46 (td, J = 9.7, 4.2 Hz, 2H), 3.23 – 3.14 (m, 2H), 2.12 – 1.95 (m, 4H), 1.92 (s, 1H), 1.36
(d, J = 7.1 Hz, 3H) ppm; 13C NMR (126 MHz, CDCl3) δ 156.4, 151.8, 140.2, 137.8, 128.5,
128.4, 127.8, 127.6, 127.5, 127.4, 123.5, 107.2, 105.5, 80.8, 73.4, 70.5, 62.6, 60.1, 56.1,
48.9, 46.3, 28.4, 23.3, 17.4 ppm; HRMS calculated for C29H35N2O5S (M+H)+ 523.2267;
found 523.2257 (TOF MS ES+).
(S)-4-((Benzyloxy)methyl)-7-((R)-2-(hydroxymethyl)pyrrolidin-1-yl)-2-((R)-1-phenylethyl)-3,4-
dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (19)
Utilizing general procedure B, sultam 19 was isolated (94%, 112 mg, 0.216 mmol) as a
colorless viscous oil; [α]D20 = + 38.6° (c = 1.95, CHCl3); FTIR (neat): 3369, 2931, 1598,
1494, 1377, 1325, 1132, 1076 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.68 – 7.65 (m, 1H),
7.36 – 7.31 (m, 2H), 7.31 – 7.28 (m, 1H), 7.28 – 7.23 (m, 3H), 7.23 – 7.18 (m, 3H), 7.17
(dd, J = 7.3, 2.1 Hz, 2H), 6.42 (dd, J = 8.9, 2.4 Hz, 1H), 6.21 (d, J = 2.4 Hz, 1H), 5.32 (q, J
= 7.0 Hz, 1H), 4.48 – 4.39 (m, 2H), 3.85 (dd, J = 10.5, 6.8 Hz, 1H), 3.67 – 3.58 (m, 2H),
3.52 (dt, J = 14.9, 7.7 Hz, 2H), 3.45 – 3.39 (m, 2H), 3.30 – 3.23 (m, 1H), 3.15 (dt, J = 15.8,
8.0 Hz, 1H), 2.07 (dd, J = 8.0, 5.2 Hz, 2H), 2.04 – 1.96 (m, 2H), 1.91 (s, 1H), 1.55 (d, J =
7.0 Hz, 3H) ppm; 13C NMR (126 MHz, CDCl3) δ 156.3, 151.7, 139.7, 137.9, 128.6, 128.5,
128.4, 127.9, 127.8, 127.7, 127.4, 122.6, 107.0, 104.6, 78.8, 73.0, 70.3, 62.6, 60.2, 56.3,
48.8, 45.9, 28.4, 23.3, 17.7 ppm; HRMS calculated for C29H35N2O5S (M+H)+ 523.2267;
found 523.2262 (TOF MS ES+).
(S)-4-((Benzyloxy)methyl)-7-((R)-2-(hydroxymethyl)pyrrolidin-1-yl)-2-((S)-1-phenylethyl)-3,4-
dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (20)
Utilizing general procedure B, sultam 20 was isolated (97%, 116 mg, 0.223 mmol) as a
colorless viscous oil; [α]D20 = + 21.7° (c = 2.6, CHCl3); FTIR (neat): 3352, 2941, 1596,
1494, 1377, 1326, 1132, 1074 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.64 (d, J = 8.8 Hz,
1H), 7.39 (m, 2H), 7.36 – 7.31 (m, 4H), 7.31 – 7.28 (m, 2H), 7.26 (m, 2H), 6.42 (dd, J = 8.8,
2.4 Hz, 1H), 6.34 (d, J = 2.4 Hz, 1H), 5.42 (q, J = 7.1 Hz, 1H), 4.53 (q, J = 11.9 Hz, 2H),
4.16 (ddd, J = 10.4, 5.9, 4.6 Hz, 1H), 3.86 (td, J = 7.2, 4.1 Hz, 1H), 3.72 (dt, J = 10.4, 5.2
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Hz, 1H), 3.69 – 3.61 (m, 1H), 3.55 – 3.49 (m, 1H), 3.47 (dt, J = 10.6, 5.3 Hz, 1H), 3.42 (dd,
J = 12.3, 5.2 Hz, 1H), 3.21 – 3.15 (m, 2H), 2.12 – 2.05 (m, 2H), 2.05 – 1.95 (m, 4H), 1.36
(d, J = 7.1 Hz, 3H) ppm; 13C NMR (126 MHz CDCl3) δ 156.4, 151.9, 140.2, 137.8, 128.5,
128.4, 127.8, 127.7, 127.6, 127.5, 123.5, 107.1, 105.4, 80.9, 73.4, 70.6, 62.6, 60.3, 56.1,
48.9, 46.3, 28.4, 23.3, 17.4 ppm; HRMS calculated for C29H35N2O5S (M+H)+ 523.2267;
found 523.2261 (TOF MS ES+).
(R)-4-((Benzyloxy)methyl)-7-((R)-2-(hydroxymethyl)pyrrolidin-1-yl)-2-((S)-1-phenylethyl)-3,4-
dihydro-2H-benzo[b][1,4,5]oxathiazepine 1,1-dioxide (21)
Utilizing general procedure B, sultam 21 was isolated (92%, 110 mg, 0.211 mmol) as a
colorless viscous oil; [α]D20 = + 1.6° (c = 1.84, CHCl3); FTIR (neat): 3390, 2937, 1598,
1496, 1377, 1325, 1130, 1076 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.66 (dd, J = 8.7, 4.3
Hz, 1H), 7.36 – 7.32 (m, 2H), 7.31 – 7.28 (m, 1H), 7.27 – 7.23 (m, 2H), 7.23 – 7.16 (m, 5H),
6.41 (dt, J = 10.7, 5.4 Hz, 1H), 6.21 (d, J = 2.4 Hz, 1H), 5.33 (q, J = 7.0 Hz, 1H), 4.44 (q, J
= 12.1 Hz, 2H), 3.88 – 3.83 (m, 1H), 3.69 – 3.57 (m, 3H), 3.56 – 3.49 (m, 2H), 3.47 – 3.41
(m, 2H), 3.28 (d, J = 12.5 Hz, 1H), 3.21 – 3.13 (m, 1H), 2.11 – 1.97 (m, 4H), 1.83 (s, 1H),
1.55 (d, J = 7.0 Hz, 3H) ppm; 13C NMR (126 MHz, CDCl3) δ 156.3, 151.6, 139.7, 137.9,
128.6, 128.5, 128.4, 127.9, 127.8, 127.7, 127.4, 122.6, 107.1, 104.7, 78.9, 73.1, 70.3, 62.6,
60.0, 56.3, 48.9, 45.9, 28.4, 23.3, 17.7 ppm; HRMS calculated for C29H35N2O5S (M+H)+
523.2267; found 523.2263 (TOF MS ES+).
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Two-step synthesis of stereochemically-rich benzothiaoxazepine-1,1-dioxides.
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MACOS scale-out of optically-pure benzothiaoxazepine-1,1′-dioxides 6 -13.
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Generation of optically-pure benzosultams 14 – 21 via microwave-assisted SNAr.
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